ICU中尿液生物标志物IGFBP7与TIMP-2:急性肾损伤结局的多中心前瞻性研究
这项在西班牙巴塞罗那5家医院开展的前瞻性多中心观察性研究纳入455例ICU患者,入院时检测尿TIMP-2·IGFBP7(NephroCheck®评分),按KDIGO标准分类AKI。AKI发生率为51%(29%为短暂性,71%为持续性)。高TIMP-2·IGFBP7(>2.0)与AKI(OR 19.44)、持续性AKI(OR 4.3)及RRT需求(OR 3.93)显著相关,并与ICU住院时间延长、AKI更严重、RRT持续时间增加及死亡率升高相关。结论认为该标志物对早期AKI检测和风险分层性能中等,鉴别短暂性与持续性AKI的作用尚不一致。
要点
- 在455例混合ICU患者中,入院尿TIMP-2·IGFBP7>2.0与AKI风险显著相关(OR 19.44;95%CI 2.57-146.5;p=0.004)。
- 高TIMP-2·IGFBP7>2.0与持续性AKI相关(OR 4.3;95%CI 1.61-11.41;p=0.003),但与短暂性AKI的鉴别作用原文认为不一致。
- 高TIMP-2·IGFBP7>2.0与RRT需求相关(OR 3.93;95%CI 1.34-11.47;p=0.012),并伴随ICU住院时间延长和死亡率升高。
- TIMP-2·IGFBP7值与ICU死亡率、院内死亡率正相关,并与90天生存率降低相关。
- 原文结论:该标志物对早期AKI检测和风险分层性能中等,需进一步研究优化其指导干预的价值。
适用人群与场景
- 西班牙巴塞罗那5家医院的455例ICU患者,为异质性重症人群;入院时采集尿样进行生物标志物分析。
- 原文未提及具体的纳入标准、排除标准或亚组人群(如脓毒症、心脏术后等)。
诊断标准与关键阈值
- AKI分类采用KDIGO(Kidney Disease: Improving Global Outcomes)标准。
- 生物标志物分组界值:尿TIMP-2·IGFBP7>2.0定义为高值组(原文未给出单位)。
- AKI subtype分为短暂性(transient)与持续性(persistent),原文未给出具体定义条件。
处置流程与药物剂量
- 原文未提及基于TIMP-2·IGFBP7的具体处置流程或药物剂量方案。
- 原文仅评估标志物与RRT需求的相关性,未提供启动RRT的阈值或方案。
红旗征与不能漏的情况
- 原文未提及具体的红旗征或需立刻处理的临床情况。
研究设计与关键结果
- 研究类型:前瞻性、多中心观察性研究;样本量455例ICU患者,来自5家医院。
- AKI发生率为51%,其中29%为短暂性、71%为持续性。
- 高TIMP-2·IGFBP7(>2.0)与AKI相关:OR 19.44(95%CI 2.57-146.5),p=0.004。
- 高TIMP-2·IGFBP7(>2.0)与持续性AKI相关:OR 4.3(95%CI 1.61-11.41),p=0.003。
- 高TIMP-2·IGFBP7(>2.0)与RRT需求相关:OR 3.93(95%CI 1.34-11.47),p=0.012。
- 高TIMP-2·IGFBP7组ICU住院时间更长、AKI更严重、RRT持续时间更长、死亡率更高;TIMP-2·IGFBP7值与ICU及院内死亡率正相关,与90天生存率降低相关。
证据类型、等级与局限
- 证据类型:前瞻性多中心观察性研究(非RCT),原文未给出证据等级或推荐强度。
- 局限性:原文未明确列出局限;设计上为观察性研究,仅提示相关性而非因果,且AKI subtype定义及标志物单位未在摘要中详述。
对床旁实践的改变
- 原文提示入院尿TIMP-2·IGFBP7>2.0可用于混合ICU人群的AKI风险分层,识别RRT需求较高者,但性能仅为中等。
- 原文认为该标志物鉴别短暂性与持续性AKI的作用不一致,不支持下述结论:单凭该指标决定是否启动RRT或区分AKI类型。
- 原文未提供基于该标志物的干预方案,故不能改变现有AKI处置流程;适用人群为异质性ICU患者,不适用于原文未纳入的人群。
指南或共识出处
- 来源:Ann Intensive Care;标题:Urinary biomarkers IGFBP7 and TIMP-2 in the ICU: a multicenter prospective study on acute kidney injury outcomes;原文未提及具体指南或共识名称。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Acute kidney injury (AKI) is prevalent in critically ill patients, contributing to high morbidity, mortality, and healthcare costs. Early detection and differentiation between transient and persistent AKI are critical for guiding timely interventions. This study evaluates the NephroCheck® score, based on Tissue inhibitor of metalloproteinases-2 (TIMP-2) and Insulin-like growth factor-binding protein 7 (IGFBP7) biomarkers. The primary objective was to assess its ability to predict AKI risk and AKI subtype within the first seven days of Intensive Care Unit (ICU) admission. Secondary objectives included evaluating its association with the need for renal replacement therapy (RRT) and overall ICU outcomes in a heterogeneous critical care population.
METHODS: This prospective, multicenter observational study included 455 ICU patients from five hospitals in Barcelona, Spain. Biomarker analysis was conducted on urine samples collected at admission, and AKI was classified according to the kidney Disease: Improving Global Outcomes (KDIGO) criteria. Patients were grouped by TIMP-2·IGFBP7 values and AKI subtypes. Data was analyzed using Stata version 18.0 (StataCorp, College Station, TX).
RESULTS: AKI occurred in 51% of patients; with 29% transient and 71% persistent. High TIMP-2·IGFBP7 (TIMP-2·IGFBP7 > 2.0) levels were significantly associated with AKI (OR 19.44; 95% CI [2.57-146.5], p = 0.004), persistent AKI (OR 4.3; 95% CI [1.61-11.41], p = 0.003), and RRT requirements (OR 3.93; 95% CI [1.34-11.47], p = 0.012). Patients with high TIMP-2·IGFBP7 had longer ICU stays, more severe AKI, increased RRT duration, and higher mortality rates. TIMP-2·IGFBP7 values correlated positively with ICU and in-hospital mortality and reduced 90-day survival.
CONCLUSION: TIMP-2·IGFBP7 showed modest performance for early AKI detection, identifying RRT requirements and risk stratification in critically ill patients. While moderately effective for predicting outcomes, its role in differentiating transient from persistent AKI remains inconsistent. Further research is warranted to optimize TIMP-2·IGFBP7 guided interventions and explore its application in diverse AKI etiologies.
参考来源
- Ángeles-Sistac D, Baldirà-Martínez de Irujo J, Betbesé-Roig AJ, et al. Urinary biomarkers IGFBP7 and TIMP-2 in the ICU: a multicenter prospective study on acute kidney injury outcomes. Ann Intensive Care. 2026. PMID: 42518782. doi:10.1016/j.aicoj.2026.100111
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。